To include your compound in the COVID-19 Resource Center, submit it here.

PCR meets GeneChips

When Roche acquired Boehringer Mannheim in 1997, the idea was to combine therapeutics and diagnostics to deliver point-of-care genotyping and, ultimately, personalized medicine. The idea was hot at the time, as Genaissance Pharmaceuticals Inc. was founded in the same year to develop personalized medicine; SmithKline Beecham plc and Incyte Pharmaceuticals Inc. formed diaDexus Inc. to develop molecular diagnostics; and Millennium Pharmaceuticals Inc. formed Millennium Predictive Medicine to apply MLNM's genomics platform to develop products to diagnose, treat, manage and prevent disease.

Read the full 812 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE